TY - JOUR AU - Drake, Marcus J. AU - Canham, Luke AU - Cotterill, Nikki AU - Delgado, Debbie AU - Homewood, Jenny AU - Inglis, Kirsty AU - Johnson, Lyndsey AU - Kisanga, Mary C. AU - Owen, Denise AU - White, Paul AU - Cottrell, David PY - 2018 DA - 2018/08/06 TI - Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS) JO - BMC Neurology SP - 107 VL - 18 IS - 1 AB - Nocturia is a common urinary symptom of multiple sclerosis (MS) which can affect quality of life (QoL) adversely. Melatonin is a hormone known to regulate circadian rhythm and reduce smooth muscle activity such as in the bladder. There is limited evidence supporting use of melatonin to alleviate urinary frequency at night in the treatment of nocturia. The aim of this study was to evaluate the effect of melatonin on the mean number of nocturia episodes per night in patients with MS. SN - 1471-2377 UR - https://doi.org/10.1186/s12883-018-1114-4 DO - 10.1186/s12883-018-1114-4 ID - Drake2018 ER -